Privo Technologies

Privo Technologies

Biotechnology, 200 Corporate Pl Ste 6B, Peabody, Massachusetts, 01960, United States, 1-10 Employees

privotechnologies.com

  • twitter
  • LinkedIn

phone no Phone Number: 97********

Who is PRIVO TECHNOLOGIES

Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge,...

Read More

map
  • 200 Corporate Pl Ste 6B, Peabody, Massachusetts, 01960, United States Headquarters: 200 Corporate Pl Ste 6B, Peabody, Massachusetts, 01960, United States
  • 2016 Date Founded: 2016
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from PRIVO TECHNOLOGIES

Privo Technologies Org Chart and Mapping

Employees

Jonathan Shikora

Manager of Analytical Chemistry

Aaron Manzi

Senior Director of Research, Development, and Manufacturing

Adelaide McFarland

Research and Development Associate

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Privo Technologies

Answer: Privo Technologies's headquarters are located at 200 Corporate Pl Ste 6B, Peabody, Massachusetts, 01960, United States

Answer: Privo Technologies's phone number is 97********

Answer: Privo Technologies's official website is https://privotechnologies.com

Answer: Privo Technologies's revenue is $1 Million to $5 Million

Answer: Privo Technologies's SIC: 2834

Answer: Privo Technologies has 1-10 employees

Answer: Privo Technologies is in Biotechnology

Answer: Privo Technologies contact info: Phone number: 97******** Website: https://privotechnologies.com

Answer: Privo Technologies is a privately funded, Phase III oncology company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avoids stomach acids, can significantly reduce toxic side effects of drugs and allows for higher dosing where the drugs can be most effective all of which improve patient outcomes and compliance. Privo was founded by Manijeh Goldberg who is a seasoned executive with over 25 years of experience in the medical industry as an executive leader and a scientist in large and small start-up companies, one of which (Epicon) was acquired for $475M. Her 12 years of large company experience includes working for HP medical and Siemens Medical Systems. Manijehs MBA from MIT and MS from Harvard Medical School led to her working with Professor Robert Langer. Professor Langer has global expertise in nanotechnology and drug delivery and is now an advisor to Privo. Privo is focused on dramatically improving human health through its novel and proprietary Mucosal Delivery Particle (MDP) platform. Privos platform has both small and large molecule applications. The technologies used in Privos platform have won awards and significant grants from the FDA and NIH.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access